Page last updated: 2024-11-05

diethanolamine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

diethanolamine: RN given refers to parent cpd [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

diethanolamine : A member of the class of ethanolamines that is ethanolamine having a N-hydroxyethyl substituent. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID8113
CHEMBL ID119604
CHEBI ID28123
SCHEMBL ID5200828
SCHEMBL ID2324
MeSH IDM0073876

Synonyms (156)

Synonym
BIDD:GT0277
ethanol,2'-iminobis-
diolamine
di(2-hydroxyethyl)amine
nsc-4959
2,2'-dihydroxydiethylamine
ethanol,2'-iminodi-
nci-c55174
2,2'-iminodi-1-ethanol
2,2'-iminodiethanol
diaethanolamin
diethylolamine
bis(2-hydroxyethyl)amine
diethanolamin
wln: q2m2q
2,2'-iminobis[ethanol]
iminodiethanol
n,n-diethanolamine
diethylamine,2'-dihydroxy-
nsc4959
2-[(2-hydroxyethyl)amino]ethanol
bis-(2-hydroxy-ethyl)-amine
n,n-di(hydroxyethyl)amine
CHEBI:28123 ,
h2dea
2,2'-iminobisethanol
2,2'iminobisethanol
bis(hydroxyethyl)amine
bis-2-hydroxyethylamine
2-(2-hydroxyethylamino)ethanol
inchi=1/c4h11no2/c6-3-1-5-2-4-7/h5-7h,1-4h
ethanol, 2,2'-iminobis-
amine,diethyl,2,2'-dihydroxy diethanolamine
NCGC00091478-01
smr000112130
MLS001065608
niax deoa-lf
brn 0605315
einecs 203-868-0
ai3-15335
diethanolamin [czech]
n,n'-iminodiethanol
di(beta-hydroxyethyl)amine
diethylamine, 2,2'-dihydroxy-
diolamine (van)
diaethanolamin [german]
dabco deoa-lf
ethanol, 2,2'-iminodi-
nsc 4959
hsdb 924
n,n-bis(2-hydroxyethyl)amine
ccris 5906
C06772
111-42-2
diethanolamine
GHL.PD_MITSCHER_LEG0.542
diethanolamine, reagent grade, >=98.0%
diethanolamine, bioxtra, >=98.5%
diethanolamine (nf)
D02337
diethanolamine, acs reagent, >=98.5%
NCGC00091478-02
NCIOPEN2_008991
61791-44-4
diethanolamine, puriss. p.a., acs reagent, >=99.0% (gc)
diethanolamine, bioultra, >=99.5% (gc)
BFC20619-2EDF-4764-8E91-830AA892BD39
BMSE000371
tegoamin deoa 85
CHEMBL119604
S0376
I0008
AKOS000119884
NCGC00091478-03
NCGC00091478-04
2-[(2-hydroxyethyl)amino]ethan-1-ol
NCGC00254061-01
dtxcid601932
cas-111-42-2
dtxsid3021932 ,
tox21_300034
tox21_201701
NCGC00259250-01
HMS2269D18
61791-46-6
4-04-00-01514 (beilstein handbook reference)
diolamine [inn]
unii-aze05tdv2v
aze05tdv2v ,
diethanolamine [nf]
ec 203-868-0
FT-0624757
STL264122
trolamine impurity b [ep impurity]
diethanolamine [inci]
diethanolamine [hsdb]
diethanolamine [usp-rs]
diolamine [mart.]
diethanolamine [ii]
diethanolamine [mi]
diethanolamine [vandf]
diethanolamine [iarc]
2,2'-azanediyldiethanol
SCHEMBL5200828
SCHEMBL2324
2,2'-azanediylbis(ethan-1-ol)
diethanolamine, acs reagent grade
diethanol amine
bis-(2-hydroxyethyl)-amine
diethanolarnine
bis-(2-hydroxy-ethyl) amine
(hoch2 ch2)2nh
2-(2-hydroxy-ethylamino)ethanol
2-(2-hydroxyethylamino)-ethanol
n, n-diethanol amine
bis-(2-hydroxyethyl)amine
2-(2-hydroxy-ethylamino)-ethanol
diethanol, 2,2'-imino-
2,2'-iminobis
STR03965
bis(2-hydroxyethyl)-d8-amine
bis(2-hydroxyethyl)amine-d11
1219804-08-6
mfcd00002843
J-506841
F2190-0311
2,2'-dihydroxydiethyamine
diethanolamine, saj first grade, >=98.0%
diethanolamine, jis special grade, >=99.0%
diethanolamine, united states pharmacopeia (usp) reference standard
diethanolamine, analytical standard
diethanolamine, 99%
aliphatic amine
trolamine impurity b, european pharmacopoeia (ep) reference standard
diethanolamine, pharmaceutical secondary standard; certified reference material
diethanolamine, puriss., 99.0%
diethanolamine, lr, >=98%
diethanolamine, biochemical grade
Q418437
2-((2-hydroxyethyl)amino)ethanol
diethanolamine reagent grade 1kg
D92250
EN300-19762
BP-31238
trolamine impurity b (ep impurity)
2,2'-iminobis(ethanol)
2,2'-dihydroxydiethyl amine
di(2-hydroxyethyl) amine
diethanolamine (usp-rs)
diethanolamine (iarc)
bis-(2-hydroxy)ethylamine
diolamine (mart.)
diethanolamine (ii)
amine, diethyl, 2,2-dihydroxy-
Z104475196
2,2'-iminodiethanol (diethanolamine)

Research Excerpts

Overview

Diethanolamine (DEA) is a chemical used widely in a number of industries and is present in many consumer products. It is a major industrial chemical which has low acute toxicity, but, on repeat exposure, has significant cumulative toxicity. Diethanolamines are a precursor of N-nitrosodiethanoline (NDELA), an animal carcinogen.

ExcerptReferenceRelevance
"Diethanolamine functions as a pH adjuster; the 16 salts included in this rereview reportedly function as surfactants, emulsifying agents, viscosity increasing agents, hair or skin conditioning agents, foam boosters, or antistatic agents."( Safety Assessment of Diethanolamine and Its Salts as Used in Cosmetics.
Andersen, FA; Belsito, DV; Bergfeld, WF; Fiume, MM; Heldreth, B; Hill, RA; Klaassen, CD; Liebler, DC; Marks, JG; Shank, RC; Slaga, TJ; Snyder, PW,
)
1.17
"Diethanolamine (DEA) is a common ingredient of personal care products. "( Dose response effects of dermally applied diethanolamine on neurogenesis in fetal mouse hippocampus and potential exposure of humans.
Craciunescu, CN; Fischer, L; Guo, Z; Johnson, AR; Niculescu, MD; Zeisel, SH, 2009
)
2.06
"Diethanolamine (DEA) is a chemical used widely in a number of industries and is present in many consumer products. "( Review of the carcinogenic activity of diethanolamine and evidence of choline deficiency as a plausible mode of action.
Kamendulis, LM; Leung, HW; Stott, WT, 2005
)
2.04
"Diethanolamine (DEA) is a widely used ingredient in many consumer products and in a number of industrial applications. "( Diethanolamine alters proliferation and choline metabolism in mouse neural precursor cells.
da Costa, KA; Guo, Z; Niculescu, MD; Wu, R; Zeisel, SH, 2007
)
3.23
"Diethanolamine (DEA) is a major industrial chemical which has low acute toxicity, but, on repeat exposure, has significant cumulative toxicity. "( Metabolism, bioaccumulation, and incorporation of diethanolamine into phospholipids.
Garner, CE; Mathews, JM; Matthews, HB,
)
1.83
"Diethanolamine (DEA) is a precursor of N-nitrosodiethanolamine (NDELA), an animal carcinogen. "( Determination of diethanolamine and N-nitrosodiethanolamine in fatty acid diethanolamides.
Chou, HJ,
)
1.91

Effects

Diethanolamine (DEA) has been found to produce liver and kidney tumors in mice following lifetime dermal exposures. DEA is listed on the State of California's Proposition 65 List.

ExcerptReferenceRelevance
"Diethanolamine (DEA) has been listed on the State of California's Proposition 65 List. "( Derivation of a No-Significant-Risk-Level (NSRL) for diethanolamine (DEA).
Amacher, DE; Wang, B; Whittaker, MH, 2014
)
2.09
"Diethanolamine (DEA) has been found to produce liver and kidney tumors in mice following lifetime dermal exposures. "( Derivation of a No-significant-risk-level (NSRL) for dermal exposures to diethanolamine.
Becker, RA; Hays, SM; Hughes, B; Kirman, CR, 2016
)
2.11
"Diethanolamine (DEA) has been shown to induce liver tumours in B6C3F(1) mice in a previous 2-year dermal study. "( Investigations on cell proliferation in B6C3F(1) mouse liver by diethanolamine.
Kaufmann, W; Mellert, W; Rossbacher, R; van Ravenzwaay, B, 2004
)
2

Actions

ExcerptReferenceRelevance
"Diethanolamine is known to inhibit cellular choline uptake."( Species differences in the induction of hepatocellular DNA synthesis by diethanolamine.
Kamendulis, LM; Klaunig, JE, 2005
)
1.28

Toxicity

Diethanolamine and its salts are safe for use when formulated to be nonirritating. Dose-dependent toxic effects due to exposure to diethanolamines included hematological changes (a poorly regenerative, microcytic anemia)

ExcerptReferenceRelevance
" Dose-dependent toxic effects due to exposure to diethanolamine included hematological changes (a poorly regenerative, microcytic anemia), as well as toxic responses in the kidney (increased weight, tubular necrosis, decreased renal function, and/or tubular mineralization), brain and spinal cord (demyelination), testis (degeneration of the seminiferous tubules) and skin (site of application: ulceration, inflammation, hyperkeratosis and acanthosis)."( Toxicity of diethanolamine. 1. Drinking water and topical application exposures in F344 rats.
Bucher, JR; Hejtmancik, M; Mahler, J; Melnick, RL; Mezza, LE; Ryan, MJ; Thompson, M,
)
0.76
" Exposure to diethanolamine caused dose-dependent toxic effects in the liver (hepatocellular cytological alterations and necrosis), kidney (nephropathy and tubular epithelial necrosis in males), heart (cardiac myocyte degeneration) and skin (site of application: ulceration, inflammation, hyperkeratosis, and acanthosis)."( Toxicity of diethanolamine. 2. Drinking water and topical application exposures in B6C3F1 mice.
Bucher, JR; Hejtmancik, M; Mahler, J; Melnick, RL; Persing, RL; Singer, A,
)
0.88
" The Expert Panel concluded that these diethanolamides are safe as used when formulated to be nonirritating and when the levels of free DEA in the diethanolamides do not exceed those considered safe by the Panel."( Safety assessment of diethanolamides as used in cosmetics.
Andersen, FA; Belsito, DV; Bergfeld, WF; Fiume, MM; Heldreth, B; Hill, RA; Klaassen, CD; Liebler, DC; Marks, JG; Shank, RC; Slaga, TJ; Snyder, PW,
)
0.13
" The Panel concluded that diethanolamine and its salts are safe for use when formulated to be nonirritating."( Safety Assessment of Diethanolamine and Its Salts as Used in Cosmetics.
Andersen, FA; Belsito, DV; Bergfeld, WF; Fiume, MM; Heldreth, B; Hill, RA; Klaassen, CD; Liebler, DC; Marks, JG; Shank, RC; Slaga, TJ; Snyder, PW,
)
0.75

Pharmacokinetics

ExcerptReferenceRelevance
"In order to better understand the potential toxicity of diethanolamine (DEA) and preparatory to physiologically-based pharmacokinetic model development, the pharmacokinetics of DEA at high and low internal dose through 96-h post-dosing were determined in female Sprague-Dawley rats administered 10 or 100 mg/kg uniformly labeled 14C-DEA via intravenous injection."( The pharmacokinetics of diethanolamine in Sprague-Dawley rats following intravenous administration.
Bartels, MJ; Bormett, GA; Mendrala, AL; Stott, WT; Waechter, JM, 2001
)
0.86

Bioavailability

ExcerptReferenceRelevance
" Oral doses were well absorbed but excreted very slowly."( Diethanolamine absorption, metabolism and disposition in rat and mouse following oral, intravenous and dermal administration.
Black, SL; Garner, CE; Mathews, JM; Matthews, HB, 1997
)
1.74
" The effect of contact time, temperature, and amine concentration on the rate of absorption and the selectivity were studied by absorption experiments in a wetted wall column at atmospheric pressure and constant feed gas ratio."( Simultaneous absorption of CO2 and H2S into aqueous blends of N-methyldiethanolamine and diethanolamine.
Bandyopadhyay, SS; Mandald, B, 2006
)
0.57

Dosage Studied

ExcerptRelevanceReference
" Differences in dose-response between the drinking water and topical application exposures were attributed largely to the limited dermal absorption of this chemical."( Toxicity of diethanolamine. 1. Drinking water and topical application exposures in F344 rats.
Bucher, JR; Hejtmancik, M; Mahler, J; Melnick, RL; Mezza, LE; Ryan, MJ; Thompson, M,
)
0.51
" Oral administration of DEA to rat was by gavage of 7 mg/kg doses once and after daily repeat dosing for up to 8 weeks."( Diethanolamine absorption, metabolism and disposition in rat and mouse following oral, intravenous and dermal administration.
Black, SL; Garner, CE; Mathews, JM; Matthews, HB, 1997
)
1.74
" A slight dose-response relationship was observed."( Diethanolamine-induced occupational asthma, a case report.
Henriks-Eckerman, ML; Keskinen, H; Mäntylä, L; Nordman, H; Piipari, R; Tuomi, T; Tuppurainen, M, 1998
)
1.74
" Blood levels of DEA reflected the dosing method used; oral greater than dermal with access greater than dermal without access."( Potential mechanisms of tumorigenic action of diethanolamine in mice.
Bartels, MJ; Brzak, KA; Mar, M; Markham, DA; Stott, WT; Thornton, CM; Zeisel, SH, 2000
)
0.57
" B6C3F1 mice were dosed dermally with DEA (0, 10, 20, 40, 80, and 160 mg/kg) for 4 weeks (5 days/week)."( Diethanolamine induces hepatic choline deficiency in mice.
Gamsky, EA; Hicks, SM; Lehman-McKeeman, LD; Mar, MH; Vassallo, JD; Zeisel, SH, 2002
)
1.76
" Relevant mechanistic data provides a link between the molecular and cellular event(s) and adverse outcome, and insight into mechanism of action is critical for accurate evaluation of dose-response relationships and inter-species extrapolation."( Incorporating mechanistic data into risk assessment.
Lehman-McKeeman, LD, 2002
)
0.31
" Final mean body weights and body weight gains of dosed males and females were similar to those of the vehicle controls."( Toxicology and carcinogenesis studies of coconut oil acid diethanolamine condensate (CAS No. 68603-42-9) in F344/N rats and B6C3F1 mice (dermal studies).
, 2001
)
0.55
"Survival of dosed male and female mice was generally similar to that of the vehicle controls."( Toxicology and carcinogenesis studies of coconut oil acid diethanolamine condensate (CAS No. 68603-42-9) in F344/N rats and B6C3F1 mice (dermal studies).
, 2001
)
0.55
" The incidences of eosinophilic foci in dosed groups of male mice were increased relative to that in the vehicle controls."( Toxicology and carcinogenesis studies of coconut oil acid diethanolamine condensate (CAS No. 68603-42-9) in F344/N rats and B6C3F1 mice (dermal studies).
, 2001
)
0.55
" The severities of nephropathy in dosed female rats were increased."( Toxicology and carcinogenesis studies of coconut oil acid diethanolamine condensate (CAS No. 68603-42-9) in F344/N rats and B6C3F1 mice (dermal studies).
, 2001
)
0.55
" No NDELA was formed in rats repeatedly dermally dosed with TEA at the limits of detection in blood (0."( Investigation of the formation of N-nitrosodiethanolamine in B6C3F1 mice following topical administration of triethanolamine.
Bartels, MJ; Brzak, KA; Markham, DA; Saghir, SA; Stott, WT, 2005
)
0.59
" Timed-pregnant C57BL/6 mice were dosed dermally from gestation day 7 through 17 with DEA at 0, 20, 80, 160, 320, and 640 mg/kg body/day."( Diethanolamine alters neurogenesis and induces apoptosis in fetal mouse hippocampus.
Craciunescu, CN; Wu, R; Zeisel, SH, 2006
)
1.78
" This study was designed to establish the dose-response relationships for this effect of DEA."( Dose response effects of dermally applied diethanolamine on neurogenesis in fetal mouse hippocampus and potential exposure of humans.
Craciunescu, CN; Fischer, L; Guo, Z; Johnson, AR; Niculescu, MD; Zeisel, SH, 2009
)
0.62
"A novel and reproducible isocratic normal phase liquid chromatographic method was developed for the quantitative determination of 10 stereoisomers of Nebivolol in pharmaceutical bulk drugs and dosage forms."( A validated chiral LC method for enantiomeric separation of nebivolol stereoisomers in bulk drugs and dosage forms on amylose-based stationary phase.
Haldar, P; Padmaja Reddy, K; Visweswara Rao, K, 2014
)
0.4
" The six amines were dosed in four vehicles (water and three generic water-based MWF formulations) and analyzed using a scintillation counter or gas chromatography/mass spectrometry."( Skin absorption of six performance amines used in metalworking fluids.
Baynes, RE; Brooks, JD; Roux, LN; Yeatts, JL, 2015
)
0.42
" Data regarding the mode of action by which DEA produces these tumors were used to support a dose-response assessment that resulted in a no-significant-risk-level (NSRL) for dermal exposures to DEA."( Derivation of a No-significant-risk-level (NSRL) for dermal exposures to diethanolamine.
Becker, RA; Hays, SM; Hughes, B; Kirman, CR, 2016
)
0.67
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (1)

RoleDescription
human xenobiotic metaboliteAny human metabolite produced by metabolism of a xenobiotic compound in humans.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (1)

ClassDescription
ethanolamines
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (22)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, HADH2 proteinHomo sapiens (human)Potency35.71680.025120.237639.8107AID886; AID893
Chain B, HADH2 proteinHomo sapiens (human)Potency35.71680.025120.237639.8107AID886; AID893
pregnane X receptorRattus norvegicus (Norway rat)Potency35.48130.025127.9203501.1870AID651751
SMAD family member 2Homo sapiens (human)Potency16.65730.173734.304761.8120AID1346859; AID1346924
USP1 protein, partialHomo sapiens (human)Potency4.46680.031637.5844354.8130AID743255
SMAD family member 3Homo sapiens (human)Potency16.65730.173734.304761.8120AID1346859; AID1346924
GLI family zinc finger 3Homo sapiens (human)Potency68.58960.000714.592883.7951AID1259369
thioredoxin glutathione reductaseSchistosoma mansoniPotency17.78280.100022.9075100.0000AID485364
aldehyde dehydrogenase 1 family, member A1Homo sapiens (human)Potency28.18380.011212.4002100.0000AID1030
nuclear receptor subfamily 1, group I, member 3Homo sapiens (human)Potency15.35530.001022.650876.6163AID1224839
retinoic acid nuclear receptor alpha variant 1Homo sapiens (human)Potency52.74870.003041.611522,387.1992AID1159552; AID1159553; AID1159555
retinoid X nuclear receptor alphaHomo sapiens (human)Potency18.79070.000817.505159.3239AID1159527; AID1159531
pregnane X nuclear receptorHomo sapiens (human)Potency54.48270.005428.02631,258.9301AID1346982
estrogen nuclear receptor alphaHomo sapiens (human)Potency10.96890.000229.305416,493.5996AID743069
thyroid hormone receptor beta isoform aHomo sapiens (human)Potency31.62280.010039.53711,122.0200AID588545
nuclear factor erythroid 2-related factor 2 isoform 1Homo sapiens (human)Potency74.97800.000627.21521,122.0200AID651741
DNA polymerase iota isoform a (long)Homo sapiens (human)Potency100.00000.050127.073689.1251AID588590
gemininHomo sapiens (human)Potency0.10320.004611.374133.4983AID624296
Cellular tumor antigen p53Homo sapiens (human)Potency15.35530.002319.595674.0614AID651631
Nuclear receptor ROR-gammaHomo sapiens (human)Potency0.94390.026622.448266.8242AID651802
ATPase family AAA domain-containing protein 5Homo sapiens (human)Potency13.68540.011917.942071.5630AID651632
Ataxin-2Homo sapiens (human)Potency13.68540.011912.222168.7989AID651632
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (151)

Processvia Protein(s)Taxonomy
negative regulation of cell population proliferationCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycleCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycle G2/M phase transitionCellular tumor antigen p53Homo sapiens (human)
DNA damage responseCellular tumor antigen p53Homo sapiens (human)
ER overload responseCellular tumor antigen p53Homo sapiens (human)
cellular response to glucose starvationCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
positive regulation of miRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
negative regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
mitophagyCellular tumor antigen p53Homo sapiens (human)
in utero embryonic developmentCellular tumor antigen p53Homo sapiens (human)
somitogenesisCellular tumor antigen p53Homo sapiens (human)
release of cytochrome c from mitochondriaCellular tumor antigen p53Homo sapiens (human)
hematopoietic progenitor cell differentiationCellular tumor antigen p53Homo sapiens (human)
T cell proliferation involved in immune responseCellular tumor antigen p53Homo sapiens (human)
B cell lineage commitmentCellular tumor antigen p53Homo sapiens (human)
T cell lineage commitmentCellular tumor antigen p53Homo sapiens (human)
response to ischemiaCellular tumor antigen p53Homo sapiens (human)
nucleotide-excision repairCellular tumor antigen p53Homo sapiens (human)
double-strand break repairCellular tumor antigen p53Homo sapiens (human)
regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
protein import into nucleusCellular tumor antigen p53Homo sapiens (human)
autophagyCellular tumor antigen p53Homo sapiens (human)
DNA damage responseCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrestCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediatorCellular tumor antigen p53Homo sapiens (human)
transforming growth factor beta receptor signaling pathwayCellular tumor antigen p53Homo sapiens (human)
Ras protein signal transductionCellular tumor antigen p53Homo sapiens (human)
gastrulationCellular tumor antigen p53Homo sapiens (human)
neuroblast proliferationCellular tumor antigen p53Homo sapiens (human)
negative regulation of neuroblast proliferationCellular tumor antigen p53Homo sapiens (human)
protein localizationCellular tumor antigen p53Homo sapiens (human)
negative regulation of DNA replicationCellular tumor antigen p53Homo sapiens (human)
negative regulation of cell population proliferationCellular tumor antigen p53Homo sapiens (human)
determination of adult lifespanCellular tumor antigen p53Homo sapiens (human)
mRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
rRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
response to salt stressCellular tumor antigen p53Homo sapiens (human)
response to inorganic substanceCellular tumor antigen p53Homo sapiens (human)
response to X-rayCellular tumor antigen p53Homo sapiens (human)
response to gamma radiationCellular tumor antigen p53Homo sapiens (human)
positive regulation of gene expressionCellular tumor antigen p53Homo sapiens (human)
cardiac muscle cell apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of cardiac muscle cell apoptotic processCellular tumor antigen p53Homo sapiens (human)
glial cell proliferationCellular tumor antigen p53Homo sapiens (human)
viral processCellular tumor antigen p53Homo sapiens (human)
glucose catabolic process to lactate via pyruvateCellular tumor antigen p53Homo sapiens (human)
cerebellum developmentCellular tumor antigen p53Homo sapiens (human)
negative regulation of cell growthCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
negative regulation of transforming growth factor beta receptor signaling pathwayCellular tumor antigen p53Homo sapiens (human)
mitotic G1 DNA damage checkpoint signalingCellular tumor antigen p53Homo sapiens (human)
negative regulation of telomere maintenance via telomeraseCellular tumor antigen p53Homo sapiens (human)
T cell differentiation in thymusCellular tumor antigen p53Homo sapiens (human)
tumor necrosis factor-mediated signaling pathwayCellular tumor antigen p53Homo sapiens (human)
regulation of tissue remodelingCellular tumor antigen p53Homo sapiens (human)
cellular response to UVCellular tumor antigen p53Homo sapiens (human)
multicellular organism growthCellular tumor antigen p53Homo sapiens (human)
positive regulation of mitochondrial membrane permeabilityCellular tumor antigen p53Homo sapiens (human)
cellular response to glucose starvationCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
entrainment of circadian clock by photoperiodCellular tumor antigen p53Homo sapiens (human)
mitochondrial DNA repairCellular tumor antigen p53Homo sapiens (human)
regulation of DNA damage response, signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of neuron apoptotic processCellular tumor antigen p53Homo sapiens (human)
transcription initiation-coupled chromatin remodelingCellular tumor antigen p53Homo sapiens (human)
negative regulation of proteolysisCellular tumor antigen p53Homo sapiens (human)
negative regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
positive regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
positive regulation of RNA polymerase II transcription preinitiation complex assemblyCellular tumor antigen p53Homo sapiens (human)
positive regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
response to antibioticCellular tumor antigen p53Homo sapiens (human)
fibroblast proliferationCellular tumor antigen p53Homo sapiens (human)
negative regulation of fibroblast proliferationCellular tumor antigen p53Homo sapiens (human)
circadian behaviorCellular tumor antigen p53Homo sapiens (human)
bone marrow developmentCellular tumor antigen p53Homo sapiens (human)
embryonic organ developmentCellular tumor antigen p53Homo sapiens (human)
positive regulation of peptidyl-tyrosine phosphorylationCellular tumor antigen p53Homo sapiens (human)
protein stabilizationCellular tumor antigen p53Homo sapiens (human)
negative regulation of helicase activityCellular tumor antigen p53Homo sapiens (human)
protein tetramerizationCellular tumor antigen p53Homo sapiens (human)
chromosome organizationCellular tumor antigen p53Homo sapiens (human)
neuron apoptotic processCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycleCellular tumor antigen p53Homo sapiens (human)
hematopoietic stem cell differentiationCellular tumor antigen p53Homo sapiens (human)
negative regulation of glial cell proliferationCellular tumor antigen p53Homo sapiens (human)
type II interferon-mediated signaling pathwayCellular tumor antigen p53Homo sapiens (human)
cardiac septum morphogenesisCellular tumor antigen p53Homo sapiens (human)
positive regulation of programmed necrotic cell deathCellular tumor antigen p53Homo sapiens (human)
protein-containing complex assemblyCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to endoplasmic reticulum stressCellular tumor antigen p53Homo sapiens (human)
thymocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of thymocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
necroptotic processCellular tumor antigen p53Homo sapiens (human)
cellular response to hypoxiaCellular tumor antigen p53Homo sapiens (human)
cellular response to xenobiotic stimulusCellular tumor antigen p53Homo sapiens (human)
cellular response to ionizing radiationCellular tumor antigen p53Homo sapiens (human)
cellular response to gamma radiationCellular tumor antigen p53Homo sapiens (human)
cellular response to UV-CCellular tumor antigen p53Homo sapiens (human)
stem cell proliferationCellular tumor antigen p53Homo sapiens (human)
signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
cellular response to actinomycin DCellular tumor antigen p53Homo sapiens (human)
positive regulation of release of cytochrome c from mitochondriaCellular tumor antigen p53Homo sapiens (human)
cellular senescenceCellular tumor antigen p53Homo sapiens (human)
replicative senescenceCellular tumor antigen p53Homo sapiens (human)
oxidative stress-induced premature senescenceCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathwayCellular tumor antigen p53Homo sapiens (human)
oligodendrocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of execution phase of apoptosisCellular tumor antigen p53Homo sapiens (human)
negative regulation of mitophagyCellular tumor antigen p53Homo sapiens (human)
regulation of mitochondrial membrane permeability involved in apoptotic processCellular tumor antigen p53Homo sapiens (human)
regulation of intrinsic apoptotic signaling pathway by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of miRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
negative regulation of G1 to G0 transitionCellular tumor antigen p53Homo sapiens (human)
negative regulation of miRNA processingCellular tumor antigen p53Homo sapiens (human)
negative regulation of glucose catabolic process to lactate via pyruvateCellular tumor antigen p53Homo sapiens (human)
negative regulation of pentose-phosphate shuntCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to hypoxiaCellular tumor antigen p53Homo sapiens (human)
regulation of fibroblast apoptotic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of stem cell proliferationCellular tumor antigen p53Homo sapiens (human)
positive regulation of cellular senescenceCellular tumor antigen p53Homo sapiens (human)
positive regulation of intrinsic apoptotic signaling pathwayCellular tumor antigen p53Homo sapiens (human)
negative regulation of transcription by RNA polymerase IINuclear receptor ROR-gammaHomo sapiens (human)
xenobiotic metabolic processNuclear receptor ROR-gammaHomo sapiens (human)
regulation of glucose metabolic processNuclear receptor ROR-gammaHomo sapiens (human)
regulation of steroid metabolic processNuclear receptor ROR-gammaHomo sapiens (human)
intracellular receptor signaling pathwayNuclear receptor ROR-gammaHomo sapiens (human)
circadian regulation of gene expressionNuclear receptor ROR-gammaHomo sapiens (human)
cellular response to sterolNuclear receptor ROR-gammaHomo sapiens (human)
positive regulation of circadian rhythmNuclear receptor ROR-gammaHomo sapiens (human)
regulation of fat cell differentiationNuclear receptor ROR-gammaHomo sapiens (human)
positive regulation of DNA-templated transcriptionNuclear receptor ROR-gammaHomo sapiens (human)
adipose tissue developmentNuclear receptor ROR-gammaHomo sapiens (human)
T-helper 17 cell differentiationNuclear receptor ROR-gammaHomo sapiens (human)
regulation of transcription by RNA polymerase IINuclear receptor ROR-gammaHomo sapiens (human)
cell population proliferationATPase family AAA domain-containing protein 5Homo sapiens (human)
positive regulation of B cell proliferationATPase family AAA domain-containing protein 5Homo sapiens (human)
nuclear DNA replicationATPase family AAA domain-containing protein 5Homo sapiens (human)
signal transduction in response to DNA damageATPase family AAA domain-containing protein 5Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorATPase family AAA domain-containing protein 5Homo sapiens (human)
isotype switchingATPase family AAA domain-containing protein 5Homo sapiens (human)
positive regulation of DNA replicationATPase family AAA domain-containing protein 5Homo sapiens (human)
positive regulation of isotype switching to IgG isotypesATPase family AAA domain-containing protein 5Homo sapiens (human)
DNA clamp unloadingATPase family AAA domain-containing protein 5Homo sapiens (human)
regulation of mitotic cell cycle phase transitionATPase family AAA domain-containing protein 5Homo sapiens (human)
negative regulation of intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorATPase family AAA domain-containing protein 5Homo sapiens (human)
positive regulation of cell cycle G2/M phase transitionATPase family AAA domain-containing protein 5Homo sapiens (human)
negative regulation of receptor internalizationAtaxin-2Homo sapiens (human)
regulation of translationAtaxin-2Homo sapiens (human)
RNA metabolic processAtaxin-2Homo sapiens (human)
P-body assemblyAtaxin-2Homo sapiens (human)
stress granule assemblyAtaxin-2Homo sapiens (human)
RNA transportAtaxin-2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (44)

Processvia Protein(s)Taxonomy
transcription cis-regulatory region bindingCellular tumor antigen p53Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
cis-regulatory region sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
core promoter sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
TFIID-class transcription factor complex bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription repressor activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
protease bindingCellular tumor antigen p53Homo sapiens (human)
p53 bindingCellular tumor antigen p53Homo sapiens (human)
DNA bindingCellular tumor antigen p53Homo sapiens (human)
chromatin bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription factor activityCellular tumor antigen p53Homo sapiens (human)
mRNA 3'-UTR bindingCellular tumor antigen p53Homo sapiens (human)
copper ion bindingCellular tumor antigen p53Homo sapiens (human)
protein bindingCellular tumor antigen p53Homo sapiens (human)
zinc ion bindingCellular tumor antigen p53Homo sapiens (human)
enzyme bindingCellular tumor antigen p53Homo sapiens (human)
receptor tyrosine kinase bindingCellular tumor antigen p53Homo sapiens (human)
ubiquitin protein ligase bindingCellular tumor antigen p53Homo sapiens (human)
histone deacetylase regulator activityCellular tumor antigen p53Homo sapiens (human)
ATP-dependent DNA/DNA annealing activityCellular tumor antigen p53Homo sapiens (human)
identical protein bindingCellular tumor antigen p53Homo sapiens (human)
histone deacetylase bindingCellular tumor antigen p53Homo sapiens (human)
protein heterodimerization activityCellular tumor antigen p53Homo sapiens (human)
protein-folding chaperone bindingCellular tumor antigen p53Homo sapiens (human)
protein phosphatase 2A bindingCellular tumor antigen p53Homo sapiens (human)
RNA polymerase II-specific DNA-binding transcription factor bindingCellular tumor antigen p53Homo sapiens (human)
14-3-3 protein bindingCellular tumor antigen p53Homo sapiens (human)
MDM2/MDM4 family protein bindingCellular tumor antigen p53Homo sapiens (human)
disordered domain specific bindingCellular tumor antigen p53Homo sapiens (human)
general transcription initiation factor bindingCellular tumor antigen p53Homo sapiens (human)
molecular function activator activityCellular tumor antigen p53Homo sapiens (human)
promoter-specific chromatin bindingCellular tumor antigen p53Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingNuclear receptor ROR-gammaHomo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificNuclear receptor ROR-gammaHomo sapiens (human)
DNA-binding transcription repressor activity, RNA polymerase II-specificNuclear receptor ROR-gammaHomo sapiens (human)
DNA-binding transcription factor activityNuclear receptor ROR-gammaHomo sapiens (human)
protein bindingNuclear receptor ROR-gammaHomo sapiens (human)
oxysterol bindingNuclear receptor ROR-gammaHomo sapiens (human)
zinc ion bindingNuclear receptor ROR-gammaHomo sapiens (human)
ligand-activated transcription factor activityNuclear receptor ROR-gammaHomo sapiens (human)
sequence-specific double-stranded DNA bindingNuclear receptor ROR-gammaHomo sapiens (human)
nuclear receptor activityNuclear receptor ROR-gammaHomo sapiens (human)
protein bindingATPase family AAA domain-containing protein 5Homo sapiens (human)
ATP bindingATPase family AAA domain-containing protein 5Homo sapiens (human)
ATP hydrolysis activityATPase family AAA domain-containing protein 5Homo sapiens (human)
DNA clamp unloader activityATPase family AAA domain-containing protein 5Homo sapiens (human)
DNA bindingATPase family AAA domain-containing protein 5Homo sapiens (human)
RNA bindingAtaxin-2Homo sapiens (human)
epidermal growth factor receptor bindingAtaxin-2Homo sapiens (human)
protein bindingAtaxin-2Homo sapiens (human)
mRNA bindingAtaxin-2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (26)

Processvia Protein(s)Taxonomy
nuclear bodyCellular tumor antigen p53Homo sapiens (human)
nucleusCellular tumor antigen p53Homo sapiens (human)
nucleoplasmCellular tumor antigen p53Homo sapiens (human)
replication forkCellular tumor antigen p53Homo sapiens (human)
nucleolusCellular tumor antigen p53Homo sapiens (human)
cytoplasmCellular tumor antigen p53Homo sapiens (human)
mitochondrionCellular tumor antigen p53Homo sapiens (human)
mitochondrial matrixCellular tumor antigen p53Homo sapiens (human)
endoplasmic reticulumCellular tumor antigen p53Homo sapiens (human)
centrosomeCellular tumor antigen p53Homo sapiens (human)
cytosolCellular tumor antigen p53Homo sapiens (human)
nuclear matrixCellular tumor antigen p53Homo sapiens (human)
PML bodyCellular tumor antigen p53Homo sapiens (human)
transcription repressor complexCellular tumor antigen p53Homo sapiens (human)
site of double-strand breakCellular tumor antigen p53Homo sapiens (human)
germ cell nucleusCellular tumor antigen p53Homo sapiens (human)
chromatinCellular tumor antigen p53Homo sapiens (human)
transcription regulator complexCellular tumor antigen p53Homo sapiens (human)
protein-containing complexCellular tumor antigen p53Homo sapiens (human)
nucleusNuclear receptor ROR-gammaHomo sapiens (human)
nucleoplasmNuclear receptor ROR-gammaHomo sapiens (human)
nuclear bodyNuclear receptor ROR-gammaHomo sapiens (human)
chromatinNuclear receptor ROR-gammaHomo sapiens (human)
nucleusNuclear receptor ROR-gammaHomo sapiens (human)
Elg1 RFC-like complexATPase family AAA domain-containing protein 5Homo sapiens (human)
nucleusATPase family AAA domain-containing protein 5Homo sapiens (human)
cytoplasmAtaxin-2Homo sapiens (human)
Golgi apparatusAtaxin-2Homo sapiens (human)
trans-Golgi networkAtaxin-2Homo sapiens (human)
cytosolAtaxin-2Homo sapiens (human)
cytoplasmic stress granuleAtaxin-2Homo sapiens (human)
membraneAtaxin-2Homo sapiens (human)
perinuclear region of cytoplasmAtaxin-2Homo sapiens (human)
ribonucleoprotein complexAtaxin-2Homo sapiens (human)
cytoplasmic stress granuleAtaxin-2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (14)

Assay IDTitleYearJournalArticle
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID158688Inhibitory activity against Plasmodium falciparum1997Journal of medicinal chemistry, Oct-24, Volume: 40, Issue:22
Antimalarial activity of molecules interfering with Plasmodium falciparum phospholipid metabolism. Structure-activity relationship analysis.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (174)

TimeframeStudies, This Drug (%)All Drugs %
pre-199036 (20.69)18.7374
1990's19 (10.92)18.2507
2000's65 (37.36)29.6817
2010's46 (26.44)24.3611
2020's8 (4.60)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 69.76

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index69.76 (24.57)
Research Supply Index5.23 (2.92)
Research Growth Index4.73 (4.65)
Search Engine Demand Index119.25 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (69.76)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1 (0.54%)5.53%
Reviews8 (4.32%)6.00%
Case Studies5 (2.70%)4.05%
Observational0 (0.00%)0.25%
Other171 (92.43%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]